| 6481/13381 | US=12 / Urologia Katz A. Alternative medicine for prostate cancer: diet, vitamins, minerals, and supplements. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 207-28. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. CANCER DE PROSTATA; MEDICINA ALTERNATIVA; DIETA; VITAMINAS; MINERAIS; SUPLEMENTACAO NUTRICIONAL; INGESTAO CALORICA; OBESIDADE; QUIMIOPREVENCAO |
| 6482/13381 | US=9 / Urologia Gleave ME, Cox ME, Wang Y. Cell biology of prostate cancer and molecular targts. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 1-24. ISBN 978-1-60327-831-7. RESISTENTE A CASTRACAO CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; CLUSTERINA; HSP27; IGF-1 |
| 6483/13381 | US=12 / Urologia Levinson AW. Controversies in prostate cancer. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 229-50. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. CANCER DE PROSTATA; DIETA; FINASTERIDA; CANCER DE PROSTATA. TRATAMENTO; BRAQUITERAPIA; TERAPIA ABLATIVA |
| 6484/13381 | US=9 / Urologia Schally AV, Block NL. Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 27-39. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; SECRECAO DE LH; SECRECAO FSH; ESTEROIDES SEXUAIS; GONADOTROFINA; CASTRACAO QUIMICA; EFEITOS ANTICANCERIGENOS; CRESCIMENTO DO TUMOR; PROLIFERACAO CELULAR; RECEPTOR LHRH |
| 6485/13381 | US=109 / Câncer Wieczorek T, Longtine JA. The role of molecular probes and other markers in the diagnosis of malignancy. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 1-5. ISBN 978-0-323-05905-3. |
| 6486/13381 | US=9 / Urologia Heemers HV, Tindall DJ. Nuclear receptor coregulators: promising therapeutic targets for the treatment of prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 41-51. ISBN 978-1-60327-831-7. CANCER DE PROSTATA. TRATAMENTO; RECEPTOR DE ANDROGENO; ANDROGENO; COATIVADOR; COREPRESSOR; PROLIFERACAO CELULAR |
| 6487/13381 | US=9 / Urologia Prince DK, Hsing AW. Androgens and prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 53-9. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; ANDROGENOS; TESTOSTERONA; TERAPIA DE REPOSICAO |
| 6488/13381 | US=109 / Câncer Shaffer K. Radiographic evaluation of cancer. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 6-29. ISBN 978-0-323-05905-3. CANCER; AVALIACAO RADIOGRAFICA; IMAGEM; RADIOGRAFIA SIMPLES; EXAMES CONTRASTADOS; MAMOGRAFIA; ULTRA-SOM; TOMOGRAFIA COMPUTADORIZADA; TOMOGRAFIA POR EMISSAO DE POSITRONS; RESSONANCIA MAGNETICA (MRI); BIOPSIA GUIADA POR IMAGEM; TERAPIA GUIADA POR IMAGEM |
| 6489/13381 | US=9 / Urologia Gelmann EP. Androgen receptor biology in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 61-70. ISBN 978-1-60327-831-7. ANDROGENO RECEPTOR DE BIOLOGIA; CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; ANDROGENO; MUTACAO; COATIVADOR; BETA-CATENINA; P160 |
| 6490/13381 | US=109 / Câncer Burrell S, Van Den Abbeele AD. Nuclear medicine in oncology. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 30-59. ISBN 978-0-323-05905-3. CANCER; MEDICINA NUCLEAR; CINTILOGRAFIA OSSEA; TOMOGRAFIA POR EMISSAO DE POSITRONS; CANCER DE TIREOIDE; TUMORES NEUROENDOCRINOS; LINFONODO SENTINELA; RADIOISOTOPOS |
| 6491/13381 | US=9 / Urologia Shen HC, Taplin ME, Balk SP. Androgen receptor antagonists. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 71-81. ISBN 978-1-60327-831-7. ANTAGONISTAS DO RECEPTOR DE ANDROGENO; CANCER PROSTATA; ESTEROIDES; ESTEROIDE RECEPTOR; TESTOTERONA; DIIDROTESTOSTERONA; ANTAGONISTA; BICALUTAMIDA; FLUTAMIDA; NILUTAMIDA |
| 6492/13381 | US=109 / Câncer Haddad R, Clark JR, Suojanen JN, Colevas AD, Posner M. Cancer of the head and neck region. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 60-97. ISBN 978-0-323-05905-3. CANCER DE CABECA E PESCOCO; CANCER DE CABECA E PESCOCO. HISTOLOGIA; TUMORES DE GLANDULAS SALIVARES; CANCER DE CABECA E PESCOCO. BIOLOGIA MOLECULAR; CANCER DE CABECA E PESCOCO. ESTADIAMENTO; CANCER DE CABECA E PESCOCO. MANIFESTACOES CLINICAS |
| 6493/13381 | US=109 / Câncer Salgia R, Blanco R, Skarin AT. Lung cancer and tumors of the heart and mediastinum. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 98-159. ISBN 978-0-323-05905-3. |
| 6494/13381 | US=9 / Urologia Culig Z. 5-Alpha reductase inhibitors in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 83-9. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; 5-ALFA REDUTASE; DUTASTERIDE; FINASTERIDE; ISOENZIMA |
| 6495/13381 | US=109 / Câncer Janne PA, Wu D, Chirieac LR. Malignant mesothelioma. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 160-8. ISBN 978-0-323-05905-3. MESOTELIOMA MALIGNO; MESOTELIOMA. APRESENTACAO CLINICA; MESOTELIOMA. DIAGNOSTICO; MESOTELIOMA. ESTADIAMENTO; MESOTELIOMA. FATORES PROGNOSTICOS; MESOTELIOMA. TRATAMENTO; CIRURGIA; QUIMIOTERAPIA; IRRADIACAO |
| 6496/13381 | US=109 / Câncer Meyerhardt JA, Kulke MH, Turner JR. Cancer of the gastrointestinal tract and neuroendocrine tumors. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 169-232. ISBN 978-0-323-05905-3. CANCER DO TRATO GASTROINTESTINAL; TUMORES NEUROENDOCRINOS; CANCER ESOFAGICO; CANCER GASTRICO; CANCER PANCREATICO; CANCER HEPATOBILIAR; CANCER DE INTESTINO DELGADO; CANCER COLORRETAL; CANCER ANAL |
| 6497/13381 | US=9 / Urologia Friedlander TW, Ryan CJ. Adrenal androgen synthesis inhibitor therapies in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 91-100. ISBN 978-1-60327-831-7. SINTESE DE ANDROGENOS ADRENAIS; TERAPIAS INIBIDOR NA CASTRACAO-RESISTENTE; CANCER DE PROSTATA; TERAPIA HORMONAL SECUNDARIA; ANDROGENIOS ADRENAIS; ANDROGENO-INDEPENDENTES CANCER DE PROSTATA; CANCER DE PROSTATA HORMONIO REFRATARIO; FASE I; FASE I DE ENSAIOS CLINICOS; FARMACOCINETICA |
| 6498/13381 | US=9 / Urologia Sharifi N. Androgen deprivation therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 101-7. ISBN 978-1-60327-831-7. TERAPIA DE PRIVACAO DE ANDROGENO; TERAPIA DE PRIVACAO DE ANDROGENO; ANDROGENOS; CANCER DE PROSTATA; TESTOSTERONA |
| 6499/13381 | US=9 / Urologia Marques FZC, Reichardt JKV. Pharmacogenetics of the androgen metabolic pathway. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 109-21. ISBN 978-1-60327-831-7. FARMACOGENETICA; ANDROGENOS; DOENCA MULTIFATORIAL; CANCER DE PROSTATA; CANCER DE PROSTATA. TRATRAMENTO; CANCER DE PROSTATA. PREVENCAO; CANCER DE PROSTATA. FARMACOGENETICA |
| 6500/13381 | US=9 / Urologia Halterman P, Vogelzang NJ, Farabishahadel A, Goodman Jr OB. Mitoxantrone. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 125-31. ISBN 978-1-60327-831-7. MITOXANTRONA; DHAD; CANCER DE PROSTATA; CRPC; TERAPIA DE RESGATE |